

**INFLUENCE OF ACCEPTING BASIC ANTIRHEUMATIC THERAPY
FOR ANKYLOSING SPONDYLOARTHRITIS ON THE CLINICAL
COURSE COVID -19**

N.M. Abdurakhmanova* ; Kh.S. Ahmedov**

*Associate Professor,
Department of Internal Medicine, Tashkent Medical Academy,
Tashkent, UZBEKISTAN

Email id: abdurahmanovanargiza87@ gmail.com

**Professor,
Head of the Department of Internal Medicine,
Tashkent Medical Academy, UZBEKISTAN

DOI: 10.5958/2249-7137.2022.00709.1

ABSTRACT

The article presents data from our own studies on the clinical course of COVID-19 in patients with ankylosing spondylitis while receiving basic therapy. Patients were divided into groups: those who underwent COVID-19 against the background of basic therapy and without it. The impact of COVID-19 was compared with clinical symptoms, disease activity. According to the results of the studies, a positive effect of basic antirheumatic therapy on the course of coronavirus infection in patients with ankylosing spondylitis was revealed.

KEYWORDS: COVID-19, Ankylosing Spondylitis, Coronavirus Infection.

REFERENCES:

1. Abdurakhmanova NM High concentration of tumor necrosis factor in ankylosing spondylitis patients after COVID-19. british medical journal. Volume 1, No.1.1, January 2022
 2. Fadlallah S, Sham Eddin MS, Rahal EA. IL-17A in COVID-19 Cases: a meta-analysis. J Infect Dev Crises. 2021 Nov 30;15(11):1630-1639. doi: 10.3855/jidc.15285. PMID: 34898490.
 3. Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021 Dec;80(12):1511-1521. doi: 10.1136/annrheumdis-2021-221035. Epub 2021 Oct 6. PMID: 34615639.
 4. Pedersen SJ, Maksymowych WP. The Pathogenesis of Ankylosing Spondylitis: an Update. CurrRheumatolRep. 2019 Nov 11;21(10):58. doi: 10.1007/s11926-019-0856-3. PMID: 31712904.
 5. Raiker R, Pakhchanian H et al. Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. Clin Rheumatol. 2022;41(3):721-730. doi:10.1007/s10067-021-05979-y
-

6. Rakhimbaeva GS, Shodiev UD Postcovidcerebro-asthenic syndrome. Journal of neurology and neurosurgical research. Vol.2 (2021), p. 6-11.
7. Rakhimova MB, Kh.S. AkhmedovThe impact of sequelae of COVID-19 on the course of ankylosing spondylitis. Central Asian journal of medicine. Vol. 2021. Issue 4., p.11
8. Sieper J, Poddubny D. Axial spondyloarthritis. Lancet. 2017 Jul 1;390(10089):73-84. doi: 10.1016/S0140-6736(16)31591-4. Epub 2017 Jan 20. PMID: 28110981.
9. Sharip A, Kunz J. Understanding the Pathogenesis of Spondyloarthritis. biomolecules. 2020 Oct 20;10(10):1461. doi: 10.3390/biom10101461. PMID: 33092023; PMCID: PMC7588965.
10. Ward MM, Deodhar A, Gensler LS et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21. PMID: 31436026; PMCID: PMC6764857.
11. Wu X, Xia T, Shin WJ, et al. Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8. mBio. 2022;13(2):e0040222. doi:10.1128/mbio.00402-22